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Background: There is an unmet need for treatment options in Chinese patients with relapsed or refractory multiple
myeloma (RRMM). Lenalidomide plus low-dose dexamethasone is effective and generally well tolerated in
Caucasian RRMM patients, but no previous study has evaluated this regimen in Chinese RRMM patients.
Methods: MM-021 is a phase 2, multicenter, single-arm open-label registration trial conducted to assess the
efficacy, safety, and pharmacokinetics of lenalidomide plus low-dose dexamethasone in Chinese patients with
RRMM. Patients with ≥1 prior antimyeloma therapy received lenalidomide plus low-dose dexamethasone until
disease progression or discontinuation. Follow-up of surviving patients continued for ≥1 year after enrollment. The
lenalidomide dose was 25 mg/day, and was adjusted according to baseline renal function. Most patients had
advanced disease (85.6% had Durie-Salmon stage III) and were heavily pretreated (56.7% had received ≥4 prior
regimens; 69.5% prior thalidomide and 63.1% prior bortezomib); 5.3% had immunoglobulin D (IgD) disease.
Results: The safety population comprised 199 eligible patients. In the efficacy population (n = 187), the disease
control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.
High response rates were also achieved in patients who had renal impairment and in those with IgD disease. After
a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4–18.8 months)
and median progression-free survival was 8.3 months (95% CI 6.5–9.8). The most common grade 3–4 adverse
events (AEs) were anemia (26.1%), neutropenia (25.1%), thrombocytopenia (14.6%), pneumonia (13.1%), leukopenia
(9.5%), and decreased neutrophil count (8.5%). AEs led to lenalidomide dose reduction and/or interruption in 40.2%
of patients, and treatment discontinuation in about 9% of patients. The pharmacokinetic profile of lenalidomide
was similar to that reported in Caucasian and Japanese patients.
Conclusions: Lenalidomide plus low-dose dexamethasone was associated with a high response rate and
acceptable safety profile in heavily pretreated Chinese patients with RRMM, including those with renal impairment
and IgD subtype. These findings highlight the clinical potential of this regimen in Chinese RRMM patients who
have exhausted current treatment options.
Trial registration: China State Food and Drug Administration (SFDA) registration (CTA reference numbers:
209 L10808; 209 L10809; 209 L10810; and 209 L10811) and ClinicalTrials.gov identifier: NCT01593410.
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In China, the annual incidence of hematological malig-
nancies, including multiple myeloma (MM), is estimated
to be approximately 2 per 100,000 people [1-3]. The
introduction of innovative therapies, such as proteasome
inhibitors and immunomodulatory drugs, has improved
the prognosis for MM patients worldwide [4]. The Chinese
Multiple Myeloma Working Group treatment guidelines
currently recommend bortezomib- and thalidomide-
containing regimens for newly diagnosed MM [5], al-
though only bortezomib has been approved for the
treatment of MM in China. As MM patients will even-
tually relapse or become refractory to current treat-
ments, there is a need for new therapeutic agents to
offer more options when this occurs.
Lenalidomide in combination with dexamethasone has
recently been approved by the Chinese authorities as a
treatment for patients with relapsed or refractory MM
(RRMM) who have received ≥1 prior therapy. In this set-
ting, lenalidomide plus high-dose dexamethasone has
been shown to be superior to high-dose dexamethasone
alone in phase 3 studies [6,7]. The combination regimen
has been shown to be safe and effective in various
RRMM patient populations, including those in North
America, Australia, Europe, Israel, and Japan [6-8]. The
pharmacokinetic (PK) profile of lenalidomide does not
appear to be sensitive to ethnic factors and has been
reported as similar in Japanese MM patients, healthy
Caucasian volunteers [8], and MM patients [9] over the
clinical dose range of 5–25 mg/day. In a study con-
ducted by the Eastern Cooperative Oncology Group
(ECOG) in patients with newly diagnosed MM, 1-year
survival was superior with lenalidomide plus low-dose
dexamethasone compared with lenalidomide plus high-
dose dexamethasone [10]. However, the lenalidomide
plus low-dose dexamethasone regimen has not been
studied in patients with RRMM. The MM-021 China
Registration study was conducted to assess the efficacy,
safety, and PK profile of lenalidomide plus low-dose
dexamethasone in Chinese patients with RRMM. The
study is registered at ClinicalTrials.gov (NCT01593410)
and with the China State Food and Drug Administration
(SFDA) (CTA reference numbers: 209 L10808; 209 L10809;
209 L10810; and 209 L10811).
Methods
MM-021 was designed and monitored in accordance
with the ethical principles of good clinical practice and
the Declaration of Helsinki, and was approved by an In-
dependent Ethics Committee. Patients provided written
informed consent prior to enrollment. The primary ob-
jective was to determine the efficacy of lenalidomide
plus low-dose dexamethasone in Chinese patients with
RRMM. The secondary objectives were to determine thesafety of lenalidomide plus low-dose dexamethasone and
the PK of lenalidomide when administered alone or with
low-dose dexamethasone in this population. The co-
authors analyzed and interpreted data; all authors had
access to the primary clinical trial data.
Study design
MM-021 is phase 2, open-label, multicenter, single-arm
trial that enrolled RRMM patients between September
12, 2010 and June 3, 2011. The data cutoff date for the
final analysis was September 26, 2012. For the PK assess-
ment, a target sample size of 10 patients was required to
obtain reasonable estimates of systemic exposure to
lenalidomide in patients with adequate renal function.
The first 11 enrolled patients aged ≤75 years who had a
baseline creatinine clearance (CLCr) of ≥60 ml/min were
included in the PK assessment cohort. Subsequent pa-
tients were enrolled in the treatment cohort without PK
assessments. Lenalidomide plus low-dose dexametha-
sone therapy was given in both cohorts until disease
progression or treatment discontinuation. All patients
(including those who discontinued treatment for any
reason) were followed up for survival and subsequent
antimyeloma treatments every 4 months (±7 days) for
≥1 year after enrollment.
Inclusion and exclusion criteria
Eligible patients were aged ≥18 years, had Durie-Salmon
MM stage II or III, and had disease progression after
≥2 cycles of antimyeloma treatment or relapsed with
progressive disease after therapy. Other inclusion criteria
were: measurable levels of M-protein in serum (≥0.5 g/dl)
or urine (≥0.2 g/24 hours); an ECOG Performance Status
score of ≤2; an absolute neutrophil count (ANC) of ≥1000
cells/mm3 (≥1.0 × 109/l); a platelet count of ≥50,000/mm3
(≥50 × 109/l); a serum transaminase level of ≤3.0 × the
upper limit of normal; and a serum total bilirubin level of
≤2.0 mg/dl (≤34 μmol/l). Females of childbearing potential
were eligible if they agreed to use ≥2 forms of reliable
contraception, have two medically supervised pregnancy
tests, and not breastfeed during the study. Males were also
required to use contraception throughout study drug ther-
apy, during any dose interruption, and for ≥28 days fol-
lowing study drug discontinuation.
Patients were excluded if they had non-secretory MM;
renal failure requiring dialysis; significant active cardiac
disease within the past 6 months (including angina re-
quiring medical intervention, uncontrolled hypertension,
myocardial infarction, New York Heart Association class
II–IV congestive heart failure, or unstable angina); history
of deep-vein thrombosis (DVT) or pulmonary embolism
(PE) within the past 12 months; prior malignancy; hyper-
sensitivity to thalidomide or dexamethasone; or prior use
of lenalidomide.
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(VTE) received anticoagulation therapy with a low-
molecular-weight heparin or full-dose warfarin for at
least the first 4 months, followed by low-dose aspirin
(70–100 mg/day) or continued anticoagulation at the
discretion of the treating physician. All other patients re-
ceived, at the discretion of the treating physician, either
oral low-dose aspirin or another prophylactic anti-
thrombotic treatment during their participation in the
study. Patients unable or unwilling to undergo anti-
thrombotic prophylactic treatment were not eligible to
participate in this study.
Treatment
Commercial formulations of lenalidomide and dexa-
methasone were supplied by Celgene Corporation.
Lenalidomide was packaged in 11- and 21-count blister
cards for the 5, 10, 15, and 25 mg capsules. Dexametha-
sone was supplied as 4 mg tablets. Lenalidomide dosing
followed the approved product labels [11,12]. The dose
of dexamethasone was based on data from a previous
randomized study which reported that a lower dose of
dexamethasone combined with lenalidomide was effect-
ive in the treatment of MM, and was associated with
better tolerability compared with lenalidomide and high-
dose dexamethasone [10].
Lenalidomide was given orally once daily on days 1–
21 of each 28-day cycle; the starting dose was 25 mg/day
for patients with normal renal function (CLCr ≥60 ml/min),
10 mg/day for those with mild-to-moderate renal insuf-
ficiency (CLCr ≥30 to <60 ml/min), and 15 mg every
other day for those with severe renal insufficiency (CLCr
<30 ml/min) [13,14]. The dose was modified in patients
who experienced grade 4 neutropenia or thrombocyto-
penia, febrile neutropenia, or any grade ≥3 lenalidomide-
related adverse event (AE). When symptoms resolved to
grade ≤2, lenalidomide was decreased by one dose level
(dose levels decrements of 5 mg) at the start of the next
cycle; for neutropenia, granulocyte colony-stimulating fac-
tor could be initiated and the dose maintained.
Lenalidomide was discontinued for grade 4 rash, grade 4
peripheral neuropathy, or grade ≥3 DVT/PE. Patients aged
≤75 years received oral dexamethasone 40 mg/day on days
1, 8, 15, and 22 of each 28-day cycle. Patients aged
>75 years received oral dexamethasone 20 mg/day on
days 1, 8, 15, and 22 of each 28-day cycle. Dexametha-
sone dose levels were 40, 20, 12, 8, and 4 mg; dosing
was reduced by one level in patients with grade ≥2 con-
fusion, mood alteration, or muscle weakness; and grade
≥3 dyspepsia, edema, or hyperglycemia. The drug was
discontinued in the event of acute pancreatitis. Patients
in the PK cohort had PK assessments during the first
8 days of cycle 1 and did not take dexamethasone on
Day 1 of cycle 1. Blood samples were collected pre-doseand at 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours post-
dose on Days 1, 7, and 8.
Outcomes and endpoints
The primary endpoint was best overall response rate
(ORR), assessed using European Group for Blood and
Marrow Transplantation (EBMT) criteria [15], and re-
sponses were also assessed by an Independent Response
Adjudication Committee (IRAC). Very good partial re-
sponse (VGPR) was added as a subcategory of partial re-
sponse (PR), under the International Myeloma Working
Group criteria [16]. Secondary endpoints included
progression-free survival (PFS), response duration,
safety, and PK parameters of lenalidomide. AEs were
coded according to the Medical Dictionary of Regulatory
Activities version 14.0, and severity was graded ac-
cording to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 4.0. PFS
was calculated as the time between study enrollment and
first documented progressive disease or death, whichever
occurred first, based on EBMTcriteria. Patients who with-
drew from the study were censored on the date of their
last response assessment. Response duration was calcu-
lated as the time from the first response (PR or better) to
the first documented progressive disease or death, which-
ever occurred first. Time to progression (TTP) was de-
fined as time from enrollment to first documented
progressive disease. Time to response was defined as the
time from enrollment to the first documented response
(PR or better). Concentrations of lenalidomide in plasma
were determined by a validated liquid chromatography-
tandem mass spectrometry method [17].
Statistical analyses and sample size
Target accrual was 194 patients, including 184 patients
in the treatment cohort and 10 patients in the PK co-
hort. For the PK cohort, the target sample size was 10
patients, to obtain reasonable estimates of systemic ex-
posure to lenalidomide in patients with adequate renal
function.
For this analysis, the primary population (n = 187) in-
cluded the first 176 patients enrolled in the treatment
cohort and the 11 patients enrolled in the PK cohort.
The efficacy-evaluable population (n = 187) included all
patients who took ≥1 dose of the study drug, had meas-
urable disease at baseline, and had ≥1 post-baseline re-
sponse assessment. To provide the most complete safety
information, the safety population (N = 199) included all
patients who had enrolled and received ≥1 dose of study
drug before data cutoff (September 26, 2012).
The Kaplan–Meier method was used to estimate the
survival distribution function for PFS, response duration,
and overall survival. The effect of dexamethasone on
lenalidomide exposure at steady state was evaluated by
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curve (AUC), AUC from time 0 to infinity (AUC∞), and
maximum observed plasma concentration (Cmax) between
Day 7 (lenalidomide alone) and Day 8 (lenalidomide plus
low-dose dexamethasone), using an analysis of variance
model (ANOVA) with treatment as a fixed effect and pa-




A total of 199 patients were enrolled in the study and
were evaluable for safety (Figure 1). At the time of the
final analysis, 42 patients continued to receive study
treatment, 156 had discontinued, and 1 patient had com-
pleted treatment. Treatment discontinuations were due to
progressive disease (n = 110), consent withdrawal (n = 22),
death (n = 13), AEs (n = 10), or protocol violation (n = 1).
The final efficacy analysis was based on the primary effi-
cacy population of 187 patients (176 in the treatment co-
hort and 11 in the PK cohort). The median treatmentFigure 1 Patient disposition.duration was 8.3 months (range 0.9–22.9 months) and the
median number of cycles was 9 (range 1–25). The median
durations of lenalidomide and dexamethasone treatment
were 7.8 months (range 0.1–22.9 months) and 7.6 months
(range 0.0–22.8 months), respectively. The median relative
dose intensity (actual dose intensity/planned dose inten-
sity) was 1.0 for both lenalidomide (range 0.3–2.3) and
dexamethasone (range 0.4–7.0), suggesting that most pa-
tients received their dose of study medication as planned
over the course of the study. The proportion of patients
receiving the 25, 20, 15, and 10 mg doses of lenalidomide
over 12 progressive treatment cycles is shown in Figure 2.
The majority of patients per treatment cycle remained on
the 25 mg/day starting dose.
Baseline demographics
Patient characteristics at baseline are shown in Table 1.
The median age of patients in the primary efficacy popu-
lation was 60.0 years (range 35.0–81.0 years), 71.1% were
aged ≤65 years, and 62.0% were male. Most patients in
the primary population had advanced disease (85.6% had
Figure 2 Dose of lenalidomide (LEN) over 12 treatment cycles.
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treated; 56.7% had received ≥4 prior regimens and most
had received prior thalidomide (69.5%), bortezomib
(63.1%), or both (44.9%). In addition, 5.4% of patients
had the immunoglobulin D (IgD) subtype of MM. Most
patients (66.8%) had normal renal function (CLCr
≥60 ml/min), 26.7% had mild-to-moderate impairment
(CLCr ≥30 to <60 ml/min), and 6.4% had severe impair-
ment (CLCr <30 ml/min). Baseline patient characteristics
(including renal function) were comparable between the
primary and the safety populations.
Efficacy
The primary efficacy endpoint of best ORR (defined as
PR or better by IRAC assessment using EBMT criteria)
in the efficacy-evaluable population (n = 187) was 47.6%,
including 23 patients (12.3%) with a VGPR and 7 pa-
tients (3.7%) who had a complete response (CR)
(Table 2). An additional 88 patients (47.1%) achieved
stable disease (SD), resulting in a disease control rate
(SD or better) of 94.7%. The median time to response
was 1.9 months (range 0.9–10.2 months).
Secondary efficacy endpoints included PFS and response
duration in the efficacy-evaluable population (n = 187).
With a median PFS follow-up of 6.5 months (range 0.6–
20.3 months), the median PFS was 8.3 months (95% CI
6.5–9.8) (Figure 3). The majority of patients (60.6%) were
progression-free at 6 months, and approximately half the
patients (46.4%) remained progression-free at 9 months.
The median duration of response was 8.8 months (range
0.4–18.8 months).
Additional endpoints included response rates in vari-
ous subgroups based on baseline characteristics. The re-
sponse rate was 58.0% in patients who had earlier
treatment (≤2 prior therapies; n = 50) and 43.8% in
those who had received later treatment (>2 priortherapies; n = 137). Regarding the type of prior therapy,
the response rate was 46.2% in those who had previ-
ously received thalidomide (n = 130), 47.5% in those
who had previously received bortezomib (n = 118),
45.2% in those who had received both thalidomide and
bortezomib (n = 84), and 47.8% in those who had received
neither prior thalidomide nor bortezomib (n = 23). The re-
sponse rate was comparable across patient subgroups with
different degrees of renal impairment. Based on renal
function, the ORR was 50.4% in patients with normal
renal function (n = 125), 42% for those with mild-to-
moderate renal impairment (n = 50), and 41.7% in those
with severe renal impairment (n = 12). Patients with IgD
MM (n = 10), had a higher response rate than the over-
all efficacy population (response rate 70.0%, including
10% CR and 50% VGPR). However, the median duration
of response was shorter in patients with IgD MM com-
pared with the overall efficacy population, with a median
duration of response of 6.6 months (range, 4.6–
10.1 months) vs. 8.8 months (range 0.4–18.8 months) in
the efficacy-evaluable population.
Safety
The most common treatment-emergent AEs (all grades)
were anemia (60.3%), decreased neutrophil and white
blood cell counts (41.2% and 32.7%, respectively), neu-
tropenia (35.7%), thrombocytopenia (21.6%), fatigue
(19.6%), upper respiratory tract infection (19.6%), and
pneumonia (18.6%). Grade 3–4 AEs were reported in 139
of 199 patients (69.8%). The most common treatment-
emergent grade 3–4 AEs were anemia (26.1%), neutro-
penia (25.1%), thrombocytopenia (14.6%), pneumonia
(13.1%), leukopenia (9.5%), and decreased neutrophil
count (8.5%) (Table 3). One patient developed grade 3
febrile neutropenia. No grade 3–4 peripheral neuropathy
was reported. Serious AEs were reported in 58 patients







Median age, years (range) 60 (35–81) 59 (35–81)
Age distribution, n (%)
≤65 years 133 (71.1) 142 (71.4)
>65 years 54 (28.9) 57 (28.6)
Male, n (%) 116 (62.0) 125 (62.8)
Durie-Salmon baseline MM stage, n (%)
I 9 (4.8) 9 (4.5)
II 18 (9.6) 19 (9.6)
III 160 (85.6) 171 (85.9)
ECOG Performance Status score, n (%)
0 69 (36.9) 73 (36.7)
1 92 (49.2) 99 (49.7)
2 26 (13.9) 27 (13.6)
Renal function (creatinine clearance), n (%)
Normal (≥60 ml/min) 125 (66.8) 131 (65.8)
Mild-to-moderate impairment
(≥30 to <60 ml/min)
50 (26.7) 54 (27.1)
Severe impairment (<30 ml/min) 12 (6.4) 14 (7.0)
Median number of prior antimyeloma
therapies, n (range)
4 (1–15) 4 (1–15)
Number of prior antimyeloma therapies, n (%)
1–3 81 (43.3) 86 (43.2)
4–6 64 (34.2) 68 (34.2)
7–9 29 (15.5) 32 (16.1)
10–15 13 (7.0) 13 (6.5)
Prior use of thalidomide or bortezomib, n (%)
Thalidomide 130 (69.5) 137 (68.8)
Bortezomib 118 (63.1) 127 (63.8)
Thalidomide and bortezomib 84 (44.9) 90 (45.2)
Type of MM, n (%)
IgA 50 (26.7) 55 (27.6)
IgD 10 (5.4) 10 (5.0)
IgG 107 (57.2) 112 (56.3)
IgM 1 (0.5) 1 (0.5)
Missing 19 (10.2) 21 (10.6)
Abbreviations: ECOG Eastern Cooperative Oncology Group, Ig immunoglobulin,
MM multiple myeloma.
Table 2 Best response as assessed by the Independent
Response Adjudication Committee (IRAC)
Efficacy-evaluable
population (n = 187)
Overall response (CR + VGPR + PR), n (%) [95% CI] 89 (47.6) [40.4–54.8]
CR, n (%) 7 (3.7)
PR, n (%) 82 (43.9)
VGPR, n (%) 23 (12.3)
Stable disease, n (%) 88 (47.1)
Progressive disease, n (%) 10 (5.3)
Median duration of response, months (range) 8.8 (0.4–18.8)
Median time to response, months (range) 1.9 (0.9–10.2)
Abbreviations: CR Complete response, PR Partial response, VGPR Very good
partial response.
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serious AEs were pneumonia (11.6%), followed by
thrombocytopenia (3.5%), cardiac failure (2.0%), anemia
(2.0%), and renal failure (1.5%).
AEs of special interest included VTE, tumor lysis syn-
drome, and second primary malignancy (SPM). Only 1
patient (0.5%) experienced DVT, which was a serious
event that led to a dose interruption and lenalidomide
dose reduction; the patient subsequently recovered. One
other patient (0.5%) experienced tumor lysis syndromewith a fatal outcome. Another patient developed an
SPM (solid duodenal tumor) that was not considered to
be related to either lenalidomide or dexamethasone.
Treatment-emergent AEs resulted in discontinuation
of lenalidomide treatment in 18 patients (9%). Cardiac
failure, thrombocytopenia, pneumonia, and constipation
led to discontinuation of lenalidomide in 2 patients each.
No other treatment-emergent AE resulted in the discon-
tinuation of lenalidomide in >1 patient. AEs resulted in
dose reduction or interruption of lenalidomide in 80 pa-
tients (40.2%) and of dexamethasone in 87 patients
(43.7%). The most common reasons for dose reduction or
interruption of lenalidomide or dexamethasone were neu-
tropenia (16.6% and 11.6%, respectively), thrombocytopenia
(7.5% and 5.0%), decreased neutrophil count (7.5% and
6.0%), pneumonia (7.0% and 8.5%), decreased platelet
count (4.0% each), pyrexia (4.0% each), and fatigue (3.5%
and 2.0%). In total, 20 patients (10.1%) in the safety popu-
lation received blood transfusions and 5 patients (2.5%)
were treated for anemia with growth factors.
As of the date of the final analysis, 77 patients in the
safety population had died either during treatment or
during the follow-up phase of the study. Twenty-five of
these patients died within 30 days of the final dose of
study medication. The most common cause of death was
MM/disease progression (17 patients); multi-organ failure
(6 patients), cardiac failure and lung infection (4 patients
each in safety population); intracranial hemorrhage, renal
failure, and respiratory failure (3 patients each); and car-
diopulmonary failure, pneumonia, septic shock, and cere-
bral hemorrhage (2 patients each).
Pharmacokinetics
The first 11 patients enrolled in the study who were
aged ≤75 years and had a baseline CLCr of ≥60 ml/min
were enrolled in the PK cohort. When administered to
Chinese patients with RRMM under fasting conditions,
lenalidomide was absorbed and eliminated rapidly with a
median time to peak concentration of approximately
Figure 3 Kaplan–Meier curve of progression-free survival (PFS) for the primary efficacy population (n = 187).
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after both single and multiple doses (Table 4). There
were no considerable differences in any of the PK pa-
rameters between a single dose (Day 1) and multiple
doses (Day 7) of lenalidomide administration. The accu-
mulation ratio between Days 1 and 7 was 0.8 and 0.9Table 3 Grade 3–4 treatment-emergent adverse events
(AEs) reported in ≥2% of patients
Safety population (N = 199)





Non-hematologic AEs, n (%)
Pneumonia 26 (13.1)






Neutrophil count decreased 17 (8.5)
Platelet count decreased 14 (7.0)
White blood cell count decreased 14 (7.0)
Discontinuation due to AEs, n (%) 18 (9.0)for Cmax and AUC, respectively, demonstrating that
lenalidomide did not accumulate in plasma with mul-
tiple doses. There were also no apparent differences in
any of the multiple-dose PK parameters for lenalidomide
alone (Day 7) or lenalidomide plus low-dose dexametha-
sone (Day 8) (Figure 4). Lenalidomide undergoes lim-
ited metabolism and has a primarily renal route of
elimination; the lenalidomide PK parameters observed
in this study were similar to those previously reported in
Caucasian and Japanese patients with RRMM and normal
renal function (Table 5) [8,9, Celgene data on file].
The addition of dexamethasone had no effect on the
plasma exposure to lenalidomide, as indicated by the
comparison of AUC and Cmax on Day 7 (lenalidomide
alone) and Day 8 (lenalidomide plus dexamethasone).
The 90% CIs for the ratio of geometric means between
the two treatments were within the conventionally ac-
cepted equivalence limits of 80% and 125% for both
AUC and Cmax.
Discussion
In the previous pivotal, global phase 3 trials (MM-009
and MM-010), the combination of lenalidomide and
high-dose dexamethasone demonstrated significantly
greater efficacy over dexamethasone alone and was gen-
erally well tolerated in treating >700 patients with
RRMM [6,7,18]. As the Chinese registration study bridg-
ing to the pivotal global trials, the MM-021 phase 2 trial
confirmed the efficacy and safety of lenalidomide in
Table 4 Plasma lenalidomide pharmacokinetic (PK)
parameters when administered alone or in combination
with dexamethasone (PK cohort, n = 11)







(n = 11) (n = 10) (n = 10)
Tmax (h) 0.93 (0.50–3.17) 1.50 (0.50–3.08) 1.00 (0.50–2.98)
Cmax (ng/ml) 574 (28.3) 478 (19.3) 494 (19.9)
AUCt (h•ng/ml) 2323 (40.1) 1963 (36.6) 2093 (41.2)
AUC∞ (h•ng/ml) 2403 (41.2) 2141 (45.4) 2162 (42.6)
t1/2 (h) 3.34 (41.9) 2.79 (32.6) 3.08 (46.8)
CL/F (ml/min) 173 (41.2) 195 (45.4) 193 (42.6)
RAC (Cmax) NA 0.84 (29.2) NA
RAC (AUCτ) NA 0.89 (17.9) NA
aGeometric mean (geometric coefficient of variation %) data are presented for
all parameters except Tmax for which median (range) data are presented.
Abbreviations: AUC Area under the plasma concentration–time curve, AUC∞ AUC
from time 0 to infinity, CL/F Apparent total plasma clearance, Cmax Maximum
observed plasma concentration, NA Not applicable, RAC (AUCτ) Accumulation ratio
between Days 1 and 7 based on AUC, RAC (Cmax) Accumulation ratio between
Days 1 and 7 based on Cmax, t1/2 Terminal phase half-life, Tmax Time to Cmax.
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patients with RRMM.
The results of the MM-021 trial are largely consistent
with the MM-009 and MM-010 studies, despite having
been carried out in a smaller, homogeneous patientFigure 4 Mean (± standard deviation) plasma lenalidomide (LEN) con
low-dose dexamethasone (LoDEX).population that was more severely ill (>80% had Durie-
Salmon MM stage III disease) and more heavily
pretreated (91.5% had received ≥2 prior antimyeloma
therapies and 57% had received ≥4 prior antimyeloma
therapies vs. 62.3% who had received ≥2 prior therapies
in MM-009 and MM-010) [19]. The best ORR with
lenalidomide plus low-dose dexamethasone in the
MM-021 analysis was slightly lower than the best
ORR in the MM-009 and MM-010 studies (47.6% vs.
60.6%, respectively) [6,7,18], perhaps explained by dexa-
methasone dosing and disease severity differences. In the
pivotal studies, dexamethasone was given at an intense
dose and schedule for the first 4 cycles (40 mg on days 1–
4, 9–12, and 17–20; 480 mg per cycle), compared with the
low-dose dexamethasone given in the MM-021 study
(40 mg on days 1, 8, 15, and 22; 160 mg per cycle). The ra-
tionale for using low-dose dexamethasone in the MM-021
trial was based on providing better tolerability while still
achieving the synergistic activity of lenalidomide and dexa-
methasone as shown by Rajkumar et al. [10] in patients
with newly diagnosed MM.
Notably, MM-021 patients who had received ≤2 treat-
ments prior to lenalidomide and low-dose dexametha-
sone had a higher ORR (58%) than the overall efficacy
population—closer to the rate reported in the MM-009
and MM-010 studies. These findings suggest that treat-
ment outcomes may be better if lenalidomide andcentrations in the absence (Day 7) and presence (Day 8) of
Table 5 Comparison of plasma lenalidomide
pharmacokinetic parameters (administered with
dexamethasone) in different populations of patients with
relapsed myeloma and normal renal function (creatinine
clearance ≥60 mL/min)












59 (40–69) 63 (43–66) 55 (44–68)
Median body
weight, kg (range)
82 (50–118) 59 (48–75) 65 (54–84)
Median CrCl, ml/min
(range)
101 (65–155) 91 (63–135) 95 (63–154)
AUC∞ (h•ng/ml) 2124 (28.6) 2305 (23.7) 2202 (30.6)
Cmax (ng/ml) 487 (35.0) 572 (33.2) 596 (30.2)
Tmax (h) 1.0 (0.4–4.0) 1.0 (0.4–2.0) 0.93 (0.5–1.0)
CL/F (ml/min) 196 (28.7) 181 (23.7) 184 (30.7)
t1/2 (h) 3.18 (20.7) 2.70 (19.3) 3.18 (39.0)
Vz/F (litres) 54.0 (29.5) 41.8 (14.3) 50.7 (28.4)
aGeometric mean (geometric coefficient of variation%) data are presented for
all parameters except when stated as median (range).
bOnly includes patients with normal renal function (creatinine clearance
≥60 mL/min).
cSee references [8,9] and [Celgene data on file].
Abbreviations: AUC Area under the plasma concentration–time curve, AUC∞
AUC from time 0 to infinity, CL/F Apparent total plasma clearance, Cmax
Maximum observed plasma concentration, CrCL Creatinine clearance, t1/2
Terminal phase half-life, Tmax Time to Cmax, Vz/F Apparent volume of
distribution during terminal phase after non-intravenous administration.
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tial relapse) rather than after several previous therapies.
This observation is consistent with a similar analysis
based on the pivotal studies [19].
Importantly, in MM-021 the overall disease control
rate (i.e. attainment of SD or better) was 94.7%, which is
clinically meaningful considering the high percentage of
patients who had a large tumor burden, poor prognosis,
and rapidly progressing MM. The analysis for PFS at the
data cutoff is limited to a median PFS follow-up of
6.5 months; however, median duration of response in
this patient population was 8.8 months, median PFS was
8.3 months, and over half of the patients (60.6%) were
progression-free at 6 months. This represents a clinically
significant delay in disease progression in a patient
population with advanced disease who had relapsed after
>2 prior therapies. Moreover, the median PFS in MM-021
is consistent with observations of TTP observed in the
MM-009 and MM-010 studies, in which the median TTP
was 11.1 and 11.3 months, respectively [6,7].
The MM-021 analysis also included some special pa-
tient populations, including those with renal impairment
and IgD disease. Lenalidomide undergoes limitedmetabolism and has a predominantly renal route of ex-
cretion; in patients with renal impairment the plasma
concentration and half-life of the drug are significantly
higher [20]. Therefore, it is important to use lower
lenalidomide starting doses in this population. A
subanalysis of patients from the MM-009 and MM-010
studies based on renal function status indicated that,
even with dose reductions and interruptions, there were
no differences in response rates in patients with renal
impairment or failure as compared with patients with
normal renal function [14]. A prospective study of 50
patients with renal impairment or renal failure has sup-
ported these results [13]. In the MM-021 analysis of
Chinese MM patients with renal impairment (including
12 patients with severe renal impairment) a high ORR
(41.7%) was achieved. These findings, together with previ-
ous reports, indicate that with careful monitoring of cre-
atinine levels and AEs, as well as appropriate dose
adjustments, lenalidomide plus low-dose dexamethasone
is an effective and well-tolerated treatment option for pa-
tients with MM who have renal impairment.
The IgD subtype of MM is associated with severe dis-
ease, and ORRs in these patients are reportedly lower
than rates in patients with other subtypes of MM [21].
Although the IgD subtype typically occurs in <2% of
Caucasian MM patients, 5.0% of the patients enrolled in
this study had IgD subtype disease. Also, an ORR of 70%
was achieved in patients with IgD MM. Although this
was a small subgroup (n = 10), the data suggest a trend
toward high efficacy of the lenalidomide plus low-dose
dexamethasone regimen in patients with IgD MM and a
poor prognosis.
The safety data in this study were consistent with the
known safety profile of lenalidomide in the RRMM set-
ting. Overall, the main AEs in MM-021 were hema-
tologic and were manageable by dose adjustment of
lenalidomide. The most frequently reported grade 3–4
AEs were cytopenias and pneumonia, and consistent
with safety findings from the global pivotal phase 3 stud-
ies. The incidence of grade 3–4 anemia was higher in
this study than in the phase 3 studies, which may be a
result of the already high baseline incidence of anemia
(87% in MM-021), partly related to underlying disease
characteristics. Importantly, lenalidomide was not asso-
ciated with peripheral neuropathy in this study. As
expected, the most common cause of death in MM-021
was MM or complications due to disease progression.
The mortality rate and the primary causes of death were
consistent with those expected for a population of pa-
tients with RRMM. The incidence of grade 3 VTE was
lower than previously observed in phase 3 studies (11.4–
14.7%) [6,7]. Only 1 patient in this study experienced a
VTE event. This may be due to the requirement for all
patients to take antithrombotic prophylactic treatment
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this trial. Some evidence also suggests that the risk of
VTE may be generally lower in Asian populations com-
pared with Caucasian populations [22,23], including
among patients with cancer [24].
The PK profile of lenalidomide in Chinese patients
was similar to that historically reported in North American
MM patients [9]. Lenalidomide was rapidly absorbed
and eliminated, with no accumulation in plasma follow-
ing single or multiple dosing. Furthermore, the mean
plasma lenalidomide exposure levels observed in Chinese
MM patients who received the 25 mg lenalidomide dose
alone were comparable to those historically observed in
Caucasian MM patients [20]. Administration of 40 mg
of dexamethasone had no effect on the multiple-dose PK
profile of lenalidomide, as evidenced by the almost iden-
tical plasma concentration–time curves and similar
values of the PK parameters for lenalidomide alone and
lenalidomide plus low-dose dexamethasone. The PK data
are also consistent with previous observations in Japa-
nese [8] and Caucasian patients with RRMM [9, Celgene
data on file]. In RRMM patients with normal renal func-
tion, lenalidomide is rapidly absorbed and eliminated,
with no evidence of accumulation after multiple doses.
Furthermore, plasma exposure to lenalidomide (as
evidenced by the AUC∞,) was similar in the different
MM populations [8,9, Celgene data on file]. The
consistency of the PK profile with previous studies sug-
gests that the 25 mg/day starting dose of lenalidomide
should also be the same in Chinese patients as in other
populations. With progressing treatment cycles, the daily
dose of lenalidomide was remarkably stable, remaining
at 25 mg/day in around 70% of patients; the 20 mg and
15 mg dose levels were infrequently used. Approximately
20% of patients with renal impairment/renal failure
started at a dose of 10 mg/day (cycle 1). In addition to
the PK results consistent with previous studies, the effi-
cacy results achieved in this Chinese MM patient popu-
lation largely maintained on stable doses, which supports
lenalidomide 25 mg as the appropriate starting dose for
patients without renal impairment. The data also support
the same dosing guidelines for Chinese patients with
renal impairment as for Caucasian patients with renal
impairment.
In the US and in western regions of the world, treat-
ment options for patients with RRMM are evolving, al-
though there is no standard recommended regimen. In
this setting, the novel agents thalidomide, lenalidomide,
and bortezomib are widely used, often in combination
with dexamethasone [4,6,7,25-27]. Patients treated with
these novel agents have been shown to have signifi-
cantly improved response rates, PFS, and overall sur-
vival compared with a median survival of <2 years at
first relapse prior to their introduction [4,6,7,25-27].New immunomodulatory agents, such as pomalidomide
[28,29] and the second-generation proteasome inhibitor
carfilzomib [30] are now being introduced in the US
and Europe. Until now, lenalidomide was not available
for the treatment of patients with RRMM in China,
with available treatments limited to standard chemo-
therapy, and thalidomide- or bortezomib-based regi-
mens [31,32]. The approval of lenalidomide in China
therefore expands the treatment armamentarium for
Chinese patients with RRMM.Conclusions
The findings from this large phase 2 registration bridg-
ing study show that lenalidomide plus low-dose dexa-
methasone led to high ORRs and was generally well
tolerated in a Chinese MM patient population, most of
whom were heavily pretreated and had advanced
RRMM. The ORR was higher in patients who were
treated in earlier lines than in more severely ill patients.
Patients with renal impairment and the IgD disease sub-
type also had clinically meaningful response rates. Dos-
ing remained relatively stable over cycles, with AEs
generally well-managed by dosing adjustments.
Many patients with advanced RRMM in China have
already failed on thalidomide and/or bortezomib treat-
ments and are in need of additional effective regimens
to prevent further disease progression. This report sug-
gests that the lenalidomide plus low-dose dexametha-
sone regimen has the potential to fulfill an unmet
medical need for the RRMM population in China.
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